Cheng, Wenwen http://orcid.org/0000-0002-5462-8245
Gordian, Desiree
Ludwig, Mette Q. http://orcid.org/0000-0002-7814-3859
Pers, Tune H. http://orcid.org/0000-0003-0207-4831
Seeley, Randy J.
Myers, Martin G. Jr. http://orcid.org/0000-0001-9468-2046
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P01 DK117821, P01 DK117821, P01 117821, P01 DK117821)
Novo Nordisk Foundation Center for Basic Metabolic Research (NNF18CC0034900)
Novo Nordisk Fonden (NNF17SA0031406, NNF18CC0034900, NNF17SA0031406)
Article History
Received: 22 March 2022
Accepted: 13 June 2022
First Online: 25 July 2022
Competing interests
: M.G.M., T.H.P. and R.J.S. receive research support from Novo Nordisk, and M.G.M. and R.J.S. receive research support from AstraZeneca. M.G.M. is a paid consultant for AstraZeneca and Regeneron Pharmaceuticals. R.J.S. also receives research support from Fractyl and is a paid consultant for Novo Nordisk, Scohia, ShouTi Pharma and Fractyl. R.J.S. also has equity positions in Calibrate and Rewind. The other authors declare no competing interests.